" class="no-js "lang="en-US"> John Stewart - Medtech Alert
Thursday, August 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
John Stewart

John Stewart

About John Stewart

John Stewart is the Acting Director of Specialised Commissioning at NHS England. Immediately prior to that he was Director of Clinical Policy and Strategy, working for Professor Sir Bruce Keogh. Before joining NHS England, John held various senior roles within the Department of Health and the Cabinet Office for over twelve years.

Related Story

Diseases

 Thousands Of Patients To Benefit As NHS Marks 100th Fast-Tracked Cancer Drug | Pharmtech Focus

Thousands Of Patients To Benefit As NHS Marks 100th Fast-Tracked Cancer Drug

July 15 2022

Thousands of people a year with advanced breast cancer will benefit from a life-extending drug […]